Evoke Pharma to Showcase Innovative Research at ACG Meeting
Evoke Pharma, Inc. (NASDAQ: EVOK), a company specializing in pharmaceutical development for gastrointestinal diseases, is preparing to participate in the American College of Gastroenterology (ACG) Annual Scientific Meeting. The event will be held in Philadelphia, providing a platform for Evoke to present significant findings and advancements in GI treatments.
Acknowledgments for Outstanding Research
This year, Evoke will present two crucial poster sessions focused on their nasal spray product, Gimoti (metoclopramide). A particular highlight is Poster P3339, which has garnered the prestigious ACG's Outstanding Research Award in the Stomach Category. This award is exclusive, given to only the top abstract submissions in its section, recognizing outstanding contributions to the field.
Details of Poster Presentations
Evoke's poster presentations include valuable insights and findings. Here are the particulars:
- Poster Number: P1606
Session Time: Sunday, 3:30 p.m. – 7:00 p.m. ET
Presenting Authors: Richard McCallum, MD and Michael Cline, DO - Poster Number: P3339
Session Time: Monday, 10:30 a.m. – 4:15 p.m. ET
Presenting Author: David Kunkel, MD
Exhibiting GIMOTI and Expanded Initiatives
In addition to the poster presentations, Evoke Pharma will exhibit at ACG, unveiling an expanded exhibit booth that reflects its commitment to innovation. They will introduce a new marketing campaign aimed at furthering the awareness and understanding of GIMOTI. Attendees can visit booth #361 in the ACG Exhibit Hall to learn more and engage with Evoke's management and commercial team.
About Evoke Pharma’s Mission
Evoke Pharma is dedicated to addressing the needs of patients suffering from gastrointestinal disorders. The company developed GIMOTI, a nasal spray formulation designed specifically for treating symptoms associated with diabetic gastroparesis, a prevalent GI disorder that significantly impacts many lives globally.
Understanding Diabetic Gastroparesis
Diabetic gastroparesis is a challenging condition where the stomach's ability to empty is impaired. This condition can lead to extreme discomfort, including nausea, vomiting, and complications due to poor absorption of medications. Prior to the introduction of GIMOTI, metoclopramide was only available in oral and injectable forms. The FDA approval allowing GIMOTI's commercial market is a significant stepping stone for those suffering from this disorder.
Staying Connected with Evoke Pharma
For those interested in learning more about Evoke Pharma and its offerings, particularly GIMOTI, more information can be found on their official website. Additionally, individuals can follow the company’s updates and initiatives on LinkedIn and Twitter, where they share insights and developments regarding their pharmaceutical innovations.
Frequently Asked Questions
What is Evoke Pharma's primary focus?
Evoke Pharma focuses on developing treatments for gastrointestinal disorders, specifically targeting conditions like diabetic gastroparesis.
What is GIMOTI?
GIMOTI is a nasal spray formulation of metoclopramide formulated to relieve symptoms associated with diabetic gastroparesis.
Where can I find Evoke Pharma at the ACG meeting?
Evoke Pharma will be exhibiting at booth #361 in the ACG Exhibit Hall during the annual meeting.
What awards has Evoke Pharma received?
Evoke's research presentation, Poster P3339, received the ACG's Outstanding Research Award in the Stomach Category and the Presidential Poster Award.
How can I stay updated on Evoke Pharma's news?
You can follow Evoke Pharma on their LinkedIn and Twitter accounts for the latest updates and announcements.
